TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26077584

Group type: EXPERIMENTAL
Intervention: Edge-detected IMT
Number of subjects: 5468

Group type: COMPARATOR
Intervention: Manual-traced IMT
Number of subjects: 5468

Group type: EXPERIMENTAL
Intervention: Edge-detected IMT (after additional adjustment for clinic site and reader)
Number of subjects: 5468
Study: 26078575

Group type: EXPERIMENTAL
Intervention: Lugol's chromoendoscopy-guided confocal laser endomicroscopy (CLE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Chromoendoscopy-guided biopsy
Number of subjects: 52
Study: 26078787

Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels in men
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Serum PTH levels in women
Number of subjects: 698

Group type: COMPARATOR
Intervention: Control group (non-diabetic individuals)
Number of subjects: 698
Study: 26079418

Group type: EXPERIMENTAL
Intervention: Liberal diagnostic scenario for MCI classification
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Conservative diagnostic scenario for MCI classification
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Neuroimaging features comparison
Number of subjects: 153
Study: 26079776

Group type: EXPERIMENTAL
Intervention: Short-term Intensive Insulin Therapy (IIT) for 4 weeks, consisting of basal detemir and premeal insulin aspart.
Number of subjects: 62
Study: 26081121

Group type: EXPERIMENTAL
Intervention: First-degree relatives (FDR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dysglycaemic subjects
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normoglycaemic subjects
Number of subjects: 100
Study: 26081793

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 26082320

Group type: EXPERIMENTAL
Intervention: Baseline Chlamydia trachomatis infection
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: ≥2 sexual partners during follow-up
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: New sexual partner during follow-up
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Age <20 years
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Recruitment from a further education college rather than a university
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: History of vaginal discharge at baseline
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: History of pelvic pain at baseline
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis and Mycoplasma genitalium infection
Number of subjects: 2004
Study: 26082332

Group type: EXPERIMENTAL
Intervention: Onalespib (AT13387) at RP2D of 160 mg/m(2)/dose administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/week)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Onalespib (AT13387)
Number of subjects: 31
Study: 26082464

Group type: EXPERIMENTAL
Intervention: Ingestion of virulent S. Paratyphi A bacteria (NVGH308 strain) with a bicarbonate buffer solution to establish the infectious dose.
Number of subjects: 20
Study: 26082815

Group type: EXPERIMENTAL
Intervention: Oral levosimendan (0.125 to 2.0 mg daily for 18-day intervals)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral levosimendan (≥0.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral levosimendan (2.0 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 26082920

Group type: EXPERIMENTAL
Intervention: Novel brain and vestibular rehabilitation (VR) treatment for PTSD
Number of subjects: 26
Study: 26083135

Group type: EXPERIMENTAL
Intervention: Adaptive model-based dose-ranging trial
Number of subjects: 0
Study: 26083256

Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg daily in monthly cycles
Number of subjects: 22
Study: 26083430

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchanges (TPE) and rituximab, supplemented with intravenous immunoglobulin (IVIG) in later cases
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional glucocorticoid therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchanges (TPE)
Number of subjects: 11
Study: 26084369

Group type: EXPERIMENTAL
Intervention: Home visits by Community Health Workers (VHTs) combined with mobile phone consultations with professional health workers.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mobile phone consultations between VHTs and professional health workers.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Home visits made by VHTs for maternal and newborn care.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Implementation of recommended maternal and newborn care practices by VHTs.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Collaboration between VHTs and professional health workers.
Number of subjects: 36
Study: 26084397

Group type: EXPERIMENTAL
Intervention: ARAT-2 (sum score 0-6, cut-off at 2 points)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ARAT-2 at 3 days post-stroke
Number of subjects: 112
Study: 26084515

Group type: EXPERIMENTAL
Intervention: FLU-v
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26084896

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI) in the ICU
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Factors predictive of severe CVC
Number of subjects: 885
Study: 26084934

Group type: EXPERIMENTAL
Intervention: Stress Doppler echocardiography (SDE) during low-dose exercise
Number of subjects: 76

Group type: COMPARATOR
Intervention: Echocardiography at rest
Number of subjects: 76
Study: 26084989

Group type: EXPERIMENTAL
Intervention: Alisertib 30 mg BID
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alisertib 40 mg BID
Number of subjects: 36
Study: 26084990

Group type: EXPERIMENTAL
Intervention: Oral MK-2206 at a dose of 200 mg administered on days 1, 8, 15, and 22 of a 28-day cycle until progression.
Number of subjects: 21
Study: 26085490

Group type: EXPERIMENTAL
Intervention: Candidate set A (7 joints, 2 tendons)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Candidate set B (9 joints, 2 tendons)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Candidate sets A and B
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Reduced GSUS and PDUS scores
Number of subjects: 439
Study: 26086290

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26086330

Group type: EXPERIMENTAL
Intervention: Higher 24-hour RQ
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher 24-hour EE
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Spontaneous physical activity
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Awake and fed thermogenesis
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: FFM
Number of subjects: 107
Study: 26087201

Group type: EXPERIMENTAL
Intervention: Classroom endotoxin exposure
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Classroom air endotoxin levels
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Classroom settled dust endotoxin levels
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Airborne endotoxin levels in classrooms
Number of subjects: 248
Study: 26087348

Group type: EXPERIMENTAL
Intervention: Clinical catastrophizing (PCS score ≥30)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Higher PCS scores
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 105
Study: 26087668

Group type: EXPERIMENTAL
Intervention: LVAD decision-making process
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Informational needs regarding LVAD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Need for peer support
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Decisional Regret Scale
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clarification of transplant status
Number of subjects: 45
Study: 26087985

Group type: EXPERIMENTAL
Intervention: Good School Toolkit (intervention)
Number of subjects: 4138

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 4138
Study: 26088117

Group type: EXPERIMENTAL
Intervention: fMRI-based neurofeedback (fMRI-NF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26088649

Group type: EXPERIMENTAL
Intervention: Perioperative goal-directed therapy (PGDT) with standardized baseline crystalloid administration of 3 ml/kg/hour and additional boluses based on PGDT.
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Perioperative goal-directed therapy (PGDT) implementation.
Number of subjects: 330
Study: 26088768

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumefantrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monodesethylamodiaquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin, Mefloquine, Chloroquine
Number of subjects: 0
Study: 26088932

Group type: EXPERIMENTAL
Intervention: National Institutes of Health Eye Score
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Schirmer's tear test
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Lee ocular subscale
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Oxford grand total staining
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Meibomian score
Number of subjects: 210
Study: 26088933

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg orally twice daily plus lenalidomide 5 mg orally once daily on days 1-21
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ruxolitinib and lenalidomide combination therapy
Number of subjects: 31
Study: 26089177

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies
Number of subjects: 37815
Study: 26089212

Group type: EXPERIMENTAL
Intervention: AcrySof Toric IOL
Number of subjects: 75
Study: 26089222

Group type: EXPERIMENTAL
Intervention: 1200 mg of oral solithromycin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1000 mg of oral solithromycin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both doses of solithromycin (1200 mg and 1000 mg)
Number of subjects: 59
Study: 26089253

Group type: EXPERIMENTAL
Intervention: Men's Prostate Awareness Church Training (M-PACT) intervention, consisting of 4 bimonthly men's health workshops.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed-sex workshops (including women)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Men-only workshops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Encouragement for men to invite women to workshops
Number of subjects: 0
Study: 26089397

Group type: EXPERIMENTAL
Intervention: Combination chemoimmunotherapy with doxorubicin- and rituximab-based regimens; 93 patients received consolidation radiotherapy.
Number of subjects: 103
Study: 26089686

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 204
Study: 26089951

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26091915

Group type: EXPERIMENTAL
Intervention: Ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg BID days 1-3 weekly (MTD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg daily days 1-3 weekly (recommended phase II dose)
Number of subjects: 15
Study: 26092045

Group type: EXPERIMENTAL
Intervention: 100% dimethicone
Number of subjects: 58
Study: 26092537

Group type: EXPERIMENTAL
Intervention: Fingolimod therapy
Number of subjects: 27
Study: 26093174

Group type: EXPERIMENTAL
Intervention: Psoriasis
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis (AD)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control
Number of subjects: 122
Study: 26093811

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 5677

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 5677
Study: 26093862

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 800000

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 800000

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 800000

Group type: EXPERIMENTAL
Intervention: Patient-centered outcomes
Number of subjects: 800000
Study: 26093865

Group type: EXPERIMENTAL
Intervention: Secondary prevention medications (aspirin, adenosine diphosphate receptor inhibitors, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, statins)
Number of subjects: 7955

Group type: EXPERIMENTAL
Intervention: Factors associated with nonpersistence
Number of subjects: 7955

Group type: EXPERIMENTAL
Intervention: Factors associated with higher persistence
Number of subjects: 7955
Study: 26093876

Group type: EXPERIMENTAL
Intervention: Holter monitoring during and after marathon race
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Holter monitoring during marathon race
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postrace assessment of cardiac troponin and IL-6
Number of subjects: 20
Study: 26093923

Group type: EXPERIMENTAL
Intervention: Native T1 in remote myocardium (2 days post-STEMI)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Incomplete ST-segment resolution
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Log of admission C-reactive protein concentration
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Peak monocyte count
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Remote T1 at baseline
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Change in LV end-diastolic volume from baseline to 6 months
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Remote zone native T1
Number of subjects: 300
Study: 26093928

Group type: EXPERIMENTAL
Intervention: Triple Rule Out (TRO)
Number of subjects: 12834

Group type: COMPARATOR
Intervention: Coronary CT Angiography (CTA)
Number of subjects: 12834
Study: 26093953

Group type: EXPERIMENTAL
Intervention: Lipiodol localization technique
Number of subjects: 250

Group type: COMPARATOR
Intervention: Hook-wire localization technique
Number of subjects: 250
Study: 26094162

Group type: EXPERIMENTAL
Intervention: Consistent use of DMPA
Number of subjects: 682

Group type: COMPARATOR
Intervention: Pregnant women not using hormonal contraception
Number of subjects: 682

Group type: COMPARATOR
Intervention: Women neither pregnant nor using hormonal contraception
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Consistent use of DMPA with HSV2-seropositive partners
Number of subjects: 682

Group type: COMPARATOR
Intervention: Women neither pregnant nor using hormonal contraception with HSV2-seropositive partners
Number of subjects: 682
Study: 26094614

Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 100 IU/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 150 IU/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in erythrocytes (GRASPA®) at 50 IU/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in erythrocytes (GRASPA®)
Number of subjects: 30
Study: 26094738

Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha plus ribavirin (PegIFN/RBV) therapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Non-responders with high MICA level (>100 pg/mL)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: High baseline MICA level
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Low platelet count (<100,000/mm3)
Number of subjects: 105
Study: 26095067

Group type: EXPERIMENTAL
Intervention: Diabetes (DM) in individuals with latent tuberculosis (LTB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes (DM) in individuals with pulmonary tuberculosis (PTB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes (DM) in individuals with pulmonary tuberculosis (PTB), latent tuberculosis (LTB), and non-TB-infected individuals (NTB)
Number of subjects: 0
Study: 26095521

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT) for severe MPS IH
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy for attenuated MPS I
Number of subjects: 89

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 89
Study: 26095669

Group type: EXPERIMENTAL
Intervention: Alefacept (0.25 mg/kg/dose on days -40 and -9; 0.5 mg/kg/dose on days -33, -26, -19, and -12)
Number of subjects: 3
Study: 26095746

Group type: EXPERIMENTAL
Intervention: Idarucizumab (5 g intravenous)
Number of subjects: 90
Study: 26095785

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy (35 Gy in ten fractions, over 2 weeks) and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy and granulocyte-macrophage colony-stimulating factor
Number of subjects: 41
Study: 26096064

Group type: EXPERIMENTAL
Intervention: Screen time (duration of viewing TV, using computer, playing video games)
Number of subjects: 358
Study: 26096743

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26097680

Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen tablet (2 months prior to pollen season)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen tablet (4 months prior to pollen season)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Secondary efficacy measures (both post-treatment years)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 26097986

Group type: EXPERIMENTAL
Intervention: AZD3043 1-minute bolus IV infusion (1, 1.5, 2, 4, and 6 mg/kg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AZD3043 1-minute bolus followed by 30-minute infusion (0.8 + 10, 1 + 15, 3 + 30, and 4 + 40 mg/kg)
Number of subjects: 72
Study: 26098143

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β-1a (Rebif®, Merck Serono SA) 44 or 22 μg three times weekly
Number of subjects: 912

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 912
Study: 26098215

Group type: EXPERIMENTAL
Intervention: Fresolimumab (1 mg/kg, 2 doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fresolimumab (5 mg/kg, 1 dose)
Number of subjects: 15
Study: 26098589

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMR) including cine and late gadolinium enhancement (LGE) imaging
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) sequences
Number of subjects: 177

Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 177
Study: 26098748

Group type: EXPERIMENTAL
Intervention: Buparlisib (BKM120) 100 mg/day
Number of subjects: 63
Study: 26099302

Group type: EXPERIMENTAL
Intervention: Neuronal ensemble activity in motor cortex
Number of subjects: 2
Study: 26100297

Group type: EXPERIMENTAL
Intervention: EMR alert and referral system
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Counseling on teratogen exposure and contraception
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 354
Study: 26100447

Group type: EXPERIMENTAL
Intervention: f/b EVAR
Number of subjects: 268

Group type: COMPARATOR
Intervention: OSR
Number of subjects: 268
Study: 26100711

Group type: EXPERIMENTAL
Intervention: 3D regimen with ribavirin (RBV) for 8, 12, or 24 weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: 3D regimen without ribavirin (RBV) for 8, 12, or 24 weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Paritaprevir-ritonavir dose of 150/100 mg
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Treatment duration of 12 or more weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Treatment duration of 8 weeks
Number of subjects: 406
Study: 26100928

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR) for 6 weeks followed by a 6-week weight stabilisation diet
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Higher baseline A. muciniphila abundance
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Higher gene richness
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baseline A. muciniphila abundance
Number of subjects: 49
Study: 26100975

Group type: EXPERIMENTAL
Intervention: Absorb™ BVS
Number of subjects: 1000
Study: 26101020

Group type: EXPERIMENTAL
Intervention: PET CT
Number of subjects: 20
Study: 26101247

Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg per day with ovarian stimulation and embryo cryopreservation
Number of subjects: 131
Study: 26103565

Group type: EXPERIMENTAL
Intervention: Home-based telemental health treatment (behavioral activation treatment)
Number of subjects: 10
Study: 26103598

Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg day(-1))
Number of subjects: 52
Study: 26104319

Group type: EXPERIMENTAL
Intervention: Whole-body computed tomography (WBCT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional diagnostics (CR and FAST)
Number of subjects: 9
Study: 26104746

Group type: EXPERIMENTAL
Intervention: Percutaneous arrhythmia ablation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cognitive interviews
Number of subjects: 25
Study: 26104945

Group type: EXPERIMENTAL
Intervention: SBRT (Stereotactic Body Radiation Therapy)
Number of subjects: 0
Study: 26105029

Group type: EXPERIMENTAL
Intervention: Quality of care for patients hospitalised with ACS
Number of subjects: 5556

Group type: EXPERIMENTAL
Intervention: Repeated measures of health-related quality of life
Number of subjects: 5556

Group type: EXPERIMENTAL
Intervention: Information about medications and patient adherence profiles
Number of subjects: 5556

Group type: EXPERIMENTAL
Intervention: Survey of hospital facilities
Number of subjects: 5556

Group type: EXPERIMENTAL
Intervention: Morbidity and mortality data from electronic health records
Number of subjects: 5556
Study: 26105149

Group type: EXPERIMENTAL
Intervention: Initiating treatment at diagnosis
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab
Number of subjects: 2652

Group type: COMPARATOR
Intervention: Patients with transformation
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Post-transformation overall survival
Number of subjects: 2652